Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MRs Should Be Fair to Provide Drug Info: Mr Tohma of Pfizer
May 24, 2004
- Annual Business Results
May 24, 2004
- Annual Business Results
May 24, 2004
- MEDICAL DEVICE NEWS IN BRIEF
May 24, 2004
- 1st Qtr Business Results
May 24, 2004
- Sankyo, Kowa: AII Receptor Blocker Olmetec
May 24, 2004
- Eli Lilly Japan, Chugai: Evista for Postmenopausal Osteoporosis
May 24, 2004
- Kissei, Takeda: Glufast Tab
May 24, 2004
- Novartis: Visudyne for AMD
May 24, 2004
- BUSINESS NEWS IN BRIEF
May 24, 2004
- WEBSITE NEWS
May 24, 2004
- MR-kun Used by 76% of Physicians when Prescribing: So-net M3 Survey
May 24, 2004
- REGULATORY NEWS IN BRIEF
May 24, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 24, 2004
- Med Professionals Expect Latest Info on Quality, Efficacy, Safety from MRs: Survey
May 17, 2004
- 1st Qtr Business Results
May 17, 2004
- CPhI Japan 2004 Conference
May 17, 2004
- MEDICAL DEVICE NEWS IN BRIEF
May 17, 2004
- BUSINESS NEWS IN BRIEF
May 17, 2004
- Tie-up with Kowa Could Evolve into Full Integration: Mr Tamura of Nikken Chemicals
May 17, 2004
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…